Sep 13, 2018
|
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
|
Aug 29, 2018
|
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
|
Aug 7, 2018
|
Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
|
Aug 1, 2018
|
Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
|
May 29, 2018
|
Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
|
May 22, 2018
|
Ardelyx Announces Pricing of Public Offering of Common Stock
|
May 21, 2018
|
Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
|
May 21, 2018
|
Ardelyx Announces Proposed Public Offering of Common Stock
|
May 8, 2018
|
Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
|
Mar 19, 2018
|
Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
|